FABIO SANDOLI DE BRITO JUNIOR

Índice h a partir de 2011
11
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Mostrar mais
Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2022 ×

Resultados de Busca

Agora exibindo 1 - 10 de 13
  • conferenceObject
    Diabetes Mellitus in Transfemoral Transcatheter Aortic Valve Implantation: A Propensity Matched Analysis
    (2022) NIEUWKERK, Astrid van; BLANCO, Roberto; TCHETCHE, Didier; BRITO JR., Fabio; BARBANTI, Marco; KORNOWSKI, Ran; LATIB, Azeem; D'ONOFRIO, Augusto; RIBICHINI, Flavio; DOMINGUEZ, Juan Francisco Oteo; DUMONTEIL, Nicolas; ABIZAID, Alexandre; SARTORI, Samantha; D'ERRIGO, Paola; TARANTINI, Giuseppe; LUNARDI, Mattia; ORVIN, Katia; PAGNESI, Matteo; DANGAS, George; MEHRAN, Roxana; DELEWI, Ronak
  • article 8 Citação(ões) na Scopus
    Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement
    (2022) VAL, David del; ABDEL-WAHAB, Mohamed; MANGNER, Norman; DURAND, Eric; IHLEMANN, Nikolaj; URENA, Marina; PELLEGRINI, Costanza; GIANNINI, Francesco; GASIOR, Tomasz; WOJAKOWSKI, Wojtek; LANDT, Martin; AUFFRET, Vincent; SINNING, Jan Malte; CHEEMA, Asim N.; NOMBELA-FRANCO, Luis; CHAMANDI, Chekrallah; CAMPELO-PARADA, Francisco; MUNOZ-GARCIA, Erika; HERRMANN, Howard C.; TESTA, Luca; WON-KEUN, K.; CASTILLO, Juan Carlos; ALPERI, Alberto; TCHETCHE, Didier; BARTORELLI, Antonio L.; KAPADIA, Samir; STORTECKY, Stefan; AMAT-SANTOS, Ignacio; WIJEYSUNDERA, Harindra C.; LISKO, John; GUTIERREZ-IBANES, Enrique; SERRA, Vicenc; SALIDO, Luisa; ALKHODAIR, Abdullah; VENDRAMIN, Igor; CHAKRAVARTY, Tarun; LERAKIS, Stamatios; VILALTA, Victoria; REGUEIRO, Ander; ROMAGUERA, Rafael; KAPPERT, Utz; BARBANTI, Marco; MASSON, Jean-Bernard; MAES, Frederic; FIORINA, Claudia; MICELI, Antonio; KODALI, Susheel; RIBEIRO, Henrique B.; MANGIONE, Jose Armando; JR, Fabio Sandoli de Brito; DATO, Guglielmo Mario Actis; ROSATO, Francesco; FERREIRA, Maria-Cristina; LIMA, Valter Corriea de; COLAFRANCESCHI, Alexandre Siciliano; ABIZAID, Alexandre; MARINO, Marcos Antonio; ESTEVES, Vinicius; ANDREA, Julio; GODINHO, Roger R.; ALFONSO, Fernando; ELTCHANINOFF, Helene; SONDERGAARD, Lars; HIMBERT, Dominique; HUSSER, Oliver; LATIB, Azeem; BRETON, Herve Le; SERVOZ, Clement; PASCUAL, Isaac; SIDDIQUI, Saif; OLIVARES, Paolo; HERNANDEZ-ANTOLIN, Rosana; WEBB, John G.; SPONGA, Sandro; MAKKAR, Raj; KINI, Annapoorna S.; BOUKHRIS, Marouane; GERVAIS, Philippe; LINKE, Axel; CRUSIUS, Lisa; HOLZHEY, David; RODES-CABAU, Josep
    Background: Staphylococcus aureus (SA) has been extensively studied as causative microorganism of surgical prosthetic-valve infective endocarditis (IE). However, scarce evidence exists on SA IE after transcatheter aortic valve replacement (TAVR). Methods: Data were obtained from the Infectious Endocarditis After TAVR International Registry, including patients with definite IE after TAVR from 59 centres in 11 countries. Patients were divided into 2 groups according to microbiologic etiology: non-SA IE vs SA IE. Results: SA IE was identified in 141 patients out of 573 (24.6%), methicillin-sensitive SA in most cases (115/141, 81.6%). Self-expanding valves were more common than balloon-expandable valves in patients presenting with early SA IE. Major bleeding and sepsis complicating TAVR, neurologic symptoms or systemic embolism at admission, and IE with cardiac device involvement (other than the TAVR prosthesis) were associated with SA IE (P < 0.05 for all). Among patients with IE after TAVR, the likelihood of SA IE increased from 19% in the absence of those risk factors to 84.6% if > 3 risk factors were present. In-hospital (47.8% vs 26.9%; P < 0.001) and 2-year (71.5% vs 49.6%; P < 0.001) mortality rates were higher among patients with SA IE vs non-SA IE. Surgery at the time of index SA IE episode was associated with lower mortality at follow-up compared with medical therapy alone (adjusted hazard ratio 0.46, 95% CI 0.22-0.96; P = 0.038). Conclusions: SA IE represented approximately 25% of IE cases after TAVR and was associated with very high in-hospital and late mortality. The presence of some features determined a higher likelihood of SA IE and could help to orientate early antibiotic regimen selection. Surgery at index SA IE was associated with improved outcomes, and its role should be evaluated in future studies.
  • article 11 Citação(ões) na Scopus
    Outcomes in Valve-in-Valve Transcatheter Aortic Valve Implantation
    (2022) NIEUWKERK, Astrid C. van; SANTOS, Raquel B.; FERNANDEZ-NOFRERIAS, Eduard; TCHETCHE, Didier; JR, Fabio S. de Brito; BARBANTI, Marco; KORNOWSKI, Ran; LATIB, Azeem; D'ONOFRIO, Augusto; RIBICHINI, Flavio; MAINAR, Vicente; DUMONTEIL, Nicolas; BAAN, Jan; ABIZAID, Alexandre; SARTORI, Samantha; D'ERRIGO, Paola; TARANTINI, Giuseppe; LUNARDI, Mattia; ORVIN, Katia; PAGNESI, Matteo; LARRAYA, Garikoitz Lasa; GHATTAS, Angie; DANGAS, George; MEHRAN, Roxana; DELEWI, Ronak
    The use of valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is increasing, but studies evaluating clinical outcomes in these patients are scarce. Also, there are limited data to guide the choice of valve type in ViV-TAVI. Therefore, this CENTER-study evaluated clinical outcomes in patients with ViV-TAVI compared to patients with native valve TAVI (NV-TAVI). In addition, we compared outcomes in patients with ViV-TAVI treated with self-expandable versus balloon-expandable valves. A total of 256 patients with ViV-TAVI and 11333 patients with NV-TAVI were matched 1:2 using propensity score matching, resulting in 256 patients with ViV-TAVI and 512 patients with NV-TAVI. Mean age was 81 +/- 7 years, 58% were female, and the Society of Thoracic Surgeons Predicted Risk of Mortality was 6.3% (4.0% to 12.8%). Mortality rates were comparable between ViV-TAVI and NV-TAVI patients at 30 days (4.1% vs 5.9%, p = 0.30) and 1 year (14.2% vs 17.3%, p = 0.34). Stroke rates were also similar at 30 days (2.8% vs 1.8%, p = 0.38) and 1 year (4.9% vs 4.3%, p = 0.74). Permanent pacemakers were less frequently implanted in patients with ViV-TAVI (8.8% vs 15.0%, relative risk 0.59, 95% confidence interval [CI] 0.37 to 0.92, p = 0.02). Patients with ViV-TAVI were treated with self-expandable valves (n = 162) and balloon-expandable valves (n = 94). Thirty-day major bleeding was less frequent in patients with self-expandable valves (3% vs 13%, odds ratio 5.12, 95% CI 1.42 to 18.52, p = 0.01). Thirty-day mortality was numerically lower in patients with self-expandable valves (3% vs 7%, odds ratio 3.35, 95% CI 0.77 to 14.51, p = 0.11). In conclusion, ViV-TAVI seems a safe and effective treatment for failing bioprosthetic valves with low mortality and stroke rates comparable to NV-TAVI for both valve types. (C) 2022 The Author(s).
  • conferenceObject
    Predictors and outcomes of acute, sub-acute and early stroke following transcatheter aortic valve implantation
    (2022) NIEUWKERK, A. C. Van; ALFONSO, F.; TCHETCHE, D.; BRITO JR., F. S. De; BARBANTI, M.; LATIB, A.; KORNOWSKI, R.; D'ONOFRIO, A.; RIBICHINI, F.; MEHRAN, R.; DELEWI, R.
  • conferenceObject
    Outcomes in Patients With Peripheral Vascular Disease Undergoing Transcatheter Aortic Valve Implantation
    (2022) NIEUWKERK, Astrid van; TCHETCHE, Didier; BRITO JR., Fabio; BARBANTI, Marco; KORNOWSKI, Ran; LATIB, Azeem; D'ONOFRIO, Augusto; RIBICHINI, Flavio; GRACIA, Maria-Cruz Ferrer; DUMONTEIL, Nicolas; SARTORI, Samantha; D'ERRIGO, Paola; TARANTINI, Giuseppe; ORVIN, Katia; PAGNESI, Matteo; BERMUDEZ, Eduardo Pinar; DANGAS, George; MEHRAN, Roxana; DELEWI, Ronak; SOLE, Paolo Alberto Del
  • conferenceObject
    Transcatheter aortic valve implantation without contrast media technique in chronic kidney disease population - pilot study
    (2022) NICZ, P.; FREIRE, A. F. D.; FILIPPINI, F. B.; KANHOUCHE, G.; ACCORSI, T. A. D.; RIBEIRO, H. B.; LIBERATO, G.; NOMURA, C. H.; CASSAR, R. S.; VIEIRA, M. L.; MATHIAS, W.; POMERANTZEFF, P. M. A.; TARASOUTCHI, F.; ABIZAID, A.; BRITO JR., F. S. De
  • article 21 Citação(ões) na Scopus
    Surgical Treatment of Patients With Infective Endocarditis After Transcatheter Aortic Valve Implantation
    (2022) MANGNER, Norman; VAL, David del; ABDEL-WAHAB, Mohamed; CRUSIUS, Lisa; DURAND, Eric; IHLEMANN, Nikolaj; URENA, Marina; PELLEGRINI, Costanza; GIANNINI, Francesco; GASIOR, Tomasz; WOJAKOWSKI, Wojtek; LANDT, Martin; AUFFRET, Vincent; SINNING, Jan Malte; CHEEMA, Asim N.; NOMBELA-FRANCO, Luis; CHAMANDI, Chekrallah; CAMPELO-PARADA, Francisco; MUNOZ-GARCIA, Erika; HERRMANN, Howard C.; TESTA, Luca; KIM, Won-Keun; CASTILLO, Juan Carlos; ALPERI, Alberto; TCHETCHE, Didier; BARTORELLI, Antonio L.; KAPADIA, Samir; STORTECKY, Stefan; AMAT-SANTOS, Ignacio; WIJEYSUNDERA, Harindra C.; LISKO, John; GUTIERREZ-IBANES, Enrique; SERRA, Vicenc; SALIDO, Luisa; ALKHODAIR, Abdullah; LIVI, Ugolino; CHAKRAVARTY, Tarun; LERAKIS, Stamatios; VILALTA, Victoria; REGUEIRO, Ander; ROMAGUERA, Rafael; KAPPERT, Utz; BARBANTI, Marco; MASSON, Jean-Bernard; MAES, Frederic; FIORINA, Claudia; MICELI, Antonio; KODALI, Susheel; RIBEIRO, Henrique B.; MANGIONE, Jose Armando; BRITO, Fabio Sandoli de; DATO, Guglielmo Mario Actis; ROSATO, Francesco; FERREIRA, Maria-Cristina; LIMA, Valter Correia de; COLAFRANCESCHI, Alexandre Siciliano; ABIZAID, Alexandre; MARINO, Marcos Antonio; ESTEVES, Vinicius; ANDREA, Julio; GODINHO, Roger R.; ALFONSO, Fernando; ELTCHANINOFF, Helene; SONDERGAARD, Lars; HIMBERT, Dominique; HUSSER, Oliver; LATIB, Azeem; BRETON, Herve Le; SERVOZ, Clement; PASCUAL, Isaac; SIDDIQUI, Saif; OLIVARES, Paolo; HERNANDEZ-ANTOLIN, Rosana; WEBB, John G.; SPONGA, Sandro; MAKKAR, Raj; KINI, Annapoorna S.; BOUKHRIS, Marouane; GERVAIS, Philippe; COTE, Melanie; HOLZHEY, David; LINKE, Axel; RODES-CABAU, Josep
    BACKGROUND The optimal treatment of patients developing infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI) is uncertain. OBJECTIVES The goal of this study was to investigate the clinical characteristics and outcomes of patients with TAVI-IE treated with cardiac surgery and antibiotics (IE-CS) compared with patients treated with antibiotics alone (IE-AB). METHODS Crude and inverse probability of treatment weighting analyses were applied for the treatment effect of cardiac surgery vs medical therapy on 1-year all-cause mortality in patients with definite TAVI-IE. The study used data from the Infectious Endocarditis after TAVI International Registry. RESULTS Among 584 patients, 111 patients (19%) were treated with IE-CS and 473 patients (81%) with IE-AB. Compared with IE-AB, IE-CS was not associated with a lower in-hospital mortality (HRunadj: 0.85; 95% CI: 0.58-1.25) and 1-year all-cause mortality (HRunadj: 0.88; 95% CI: 0.64-1.22) in the crude cohort. After adjusting for selection and immortal time bias, IE-CS compared with IE-AB was also not associated with lower mortality rates for in-hospital mortality (HRadj: 0.92; 95% CI: 0.80-1.05) and 1-year all-cause mortality (HRadj: 0.95; 95% CI: 0.84-1.07). Results remained similar when patients with and without TAVI prosthesis involvement were analyzed separately. Predictors for in-hospital and 1-year all-cause mortality included logistic EuroSCORE I, Staphylococcus aureus, acute renal failure, persistent bacteremia, and septic shock. CONCLUSIONS In this registry, the majority of patients with TAVI-IE were treated with antibiotics alone. Cardiac surgery was not associated with an improved all-cause in-hospital or 1-year mortality. The high mortality of patients with TAVI-IE was strongly linked to patients' characteristics, pathogen, and IE-related complications. (C) 2022 by the American College of Cardiology Foundation.
  • article 0 Citação(ões) na Scopus
    Delayed left main coronary obstruction following transfemoral inovare transcatheter aortic valve replacement: A challenging case
    (2022) KANHOUCHE, G.; CIVIDANES, F. R.; SAMPAIO, R. O.; SILVA, J. C. A. da; MACHADO, R. D.; WERNECK, M.; ACCORSI, T. A. D.; MORALES, K. R. D. P.; ABIZAID, A. C.; BRITO, F. S. D. Jr.; TARASOUTCHI, F.; PALMA, J. H.; RIBEIRO, H. B.
    Coronary obstruction is an uncommon and severe complication after a transcatheter aortic valve replacement (TAVR), that occurs during the procedure in the vast majority of patients. In the present case even in the absence of classic risk factors, an acute coronary syndrome occurred one day after TAVR. Selective angiography revealed a severe left main ostium obstruction by the bulky native leaflet calcification. This is the first case of delayed presentation of coronary obstruction with a transfemoral balloon-expandable valve using the Inovare bioprosthesis (Braile Biomedica, Brazil). In addition, after drug-eluting stent placement in the left main coronary, intravascular ultrasound revealed severe stent underexpansion, so that a second layer of a bare-metal stent and high-pressure balloon post-dilatation was necessary to improve the final result. The patient was discharged after 7 days, and at the 6-month follow-up remained asymptomatic.
  • article 0 Citação(ões) na Scopus
    Diabetes mellitus in transfemoral transcatheter aortic valve implantation: a propensity matched analysis
    (2022) NIEUWKERK, Astrid C. van; SANTOS, Raquel B.; MATA, Roberto Blanco; TCHETCHE, Didier; BRITO JR., Fabio S. de; BARBANTI, Marco; KORNOWSKI, Ran; LATIB, Azeem; D'ONOFRIO, Augusto; RIBICHINI, Flavio; BAAN, Jan; OTEO-DOMINGUEZ, Juan; DUMONTEIL, Nicolas; ABIZAID, Alexandre; SARTORI, Samantha; D'ERRIGO, Paola; TARANTINI, Giuseppe; LUNARDI, Mattia; ORVIN, Katia; PAGNESI, Matteo; GHATTAS, Angie; AMAT-SANTOS, Ignacio; DANGAS, George; MEHRAN, Roxana; DELEWI, Ronak
    Background Diabetes Mellitus (DM) affects a third of patients with symptomatic severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). DM is a well-known risk factor for cardiac surgery, but its prognostic impact in TAVI patients remains controversial. This study aimed to evaluate outcomes in diabetic patients undergoing TAVI. Methods This multicentre registry includes data of > 12,000 patients undergoing transfemoral TAVI. We assessed baseline patient characteristics and clinical outcomes in patients with DM and without DM. Clinical outcomes were defined by the second valve academic research consortium. Propensity score matching was applied to minimize potential confounding. Results Of the 11,440 patients included, 31% (n = 3550) had DM and 69% (n = 7890) did not have DM. Diabetic patients were younger but had an overall worse cardiovascular risk profile than non-diabetic patients. All-cause mortality rates were comparable at 30 days (4.5% vs. 4.9%, RR 0.9, 95%CI 0.8-1.1, p = 0.43) and at one year (17.5% vs. 17.4%, RR 1.0, 95%CI 0.9-1.1, p = 0.86) in the unmatched population. Propensity score matching obtained 3281 patient-pairs. Also in the matched population, mortality rates were comparable at 30 days (4.7% vs. 4.3%, RR 1.1, 95%CI 0.9-1.4, p = 0.38) and one year (17.3% vs. 16.2%, RR 1.1, 95%CI 0.9-1.2, p = 0.37). Other clinical outcomes including stroke, major bleeding, myocardial infarction and permanent pacemaker implantation, were comparable between patients with DM and without DM. Insulin treated diabetics (n = 314) showed a trend to higher mortality compared with non-insulin treated diabetics (n = 701, Hazard Ratio 1.5, 95%CI 0.9-2.3, p = 0.08). EuroSCORE II was the most accurate risk score and underestimated 30-day mortality with an observed-expected ratio of 1.15 in DM patients, STS-PROM overestimated actual mortality with a ratio of 0.77 and Logistic EuroSCORE with 0.35. Conclusion DM was not associated with mortality during the first year after TAVI. DM patients undergoing TAVI had low rates of mortality and other adverse clinical outcomes, comparable to non-DM TAVI patients. Our results underscore the safety of TAVI treatment in DM patients.
  • article 3 Citação(ões) na Scopus
    Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation
    (2022) PANAGIDES, Vassili; VAL, David Del; ABDEL-WAHAB, Mohamed; MANGNER, Norman; DURAND, Eric; IHLEMANN, Nikolaj; URENA, Marina; PELLEGRINI, Costanza; GIANNINI, Francesco; SCISLO, Piotr; HUCZEK, Zenon; LANDT, Martin; AUFFRET, Vincent; SINNING, Jan Malte; CHEEMA, Asim N.; NOMBELA-FRANCO, Luis; CHAMANDI, Chekrallah; CAMPELO-PARADA, Francisco; MUNOZ-GARCIA, Erika; HERRMANN, Howard C.; TESTA, Luca; KIM, Won-Keun; CASTILLO, Juan Carlos; ALPERI, Alberto; TCHETCHE, Didier; BARTORELLI, Antonio L.; KAPADIA, Samir; STORTECKY, Stefan; AMAT-SANTOS, Ignacio; WIJEYSUNDERA, Harindra C.; LISKO, John; GUTIERREZ-IBANES, Enrique; SERRA, Vicenc; SALIDO, Luisa; ALKHODAIR, Abdullah; LIVI, Ugolino; CHAKRAVARTY, Tarun; LERAKIS, Stamatios; VILALTA, Victoria; REGUEIRO, Ander; ROMAGUERA, Rafael; KAPPERT, Utz; BARBANTI, Marco; MASSON, Jean-Bernard; MAES, Frederic; FIORINA, Claudia; MICELI, Antonio; KODALI, Susheel; RIBEIRO, Henrique B.; MANGIONE, Jose Armando; JR, Fabio Sandoli de Brito; DATO, Guglielmo Mario Actis; ROSATO, Francesco; FERREIRA, Maria-Cristina; LIMA, Valter Correia de; COLAFRANCESCHI, Alexandre Siciliano; ABIZAID, Alexandre; MARINO, Marcos Antonio; ESTEVES, Vinicius; ANDREA, Julio; GODINHO, Roger R.; ALFONSO, Fernando; ELTCHANINOFF, Helene; SONDERGAARD, Lars; HIMBERT, Dominique; HUSSER, Oliver; LATIB, Azeem; BRETON, Herve Le; SERVOZ, Clement; PASCUAL, Isaac; SIDDIQUI, Saif; OLIVARES, Paolo; HERNANDEZ-ANTOLIN, Rosana; WEBB, John G.; SPONGA, Sandro; MAKKAR, Raj; KINI, Annapoorna S.; BOUKHRIS, Marouane; GERVAIS, Philippe; LINKE, Axel; CRUSIUS, Lisa; HOLZHEY, David; RODES-CABAU, Josep
    Scarce data exist on mitral valve (MV) infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). This multicenter study included a total of 579 patients with a diagnosis of definite IE after TAVI from the IE after TAVI International Registry and aimed to evaluate the incidence, characteristics, management, and outcomes of MV-IE after TAVI. A total of 86 patients (14.9%) had MV-IE. These patients were compared with 284 patients (49.1%) with involvement of the transcatheter heart valve (THV) only. Two factors were found to be associated with MV-IE: the use of self-expanding valves (adjusted odds ratio 2.49, 95% confidence interval [CI] 1.23 to 5.07, p = 0.012), and the presence of an aortic regurgitation >= 2 at discharge (adjusted odds ratio 3.33; 95% CI 1.43 to 7.73, p < 0.01). There were no differences in IE timing and causative microorganisms between groups, but surgical management was significantly lower in patients with MV-IE (6.0%, vs 21.6% in patients with THV-IE, p = 0.001). All-cause mortality rates at 2-year follow-up were high and similar between patients with MV-IE (51.4%, 95% CI 39.8 to 64.1) and patients with THV-IE (51.5%, 95% CI 45.4 to 58.0) (log-rank p = 0.295). The factors independently associated with increased mortality risk in patients with MV-IE were the occurrence of heart failure (adjusted p < 0.001) and septic shock (adjusted p < 0.01) during the index hospitalization. One of 6 IE episodes after TAVI is localized on the MV. The implantation of a self-expanding THV and the presence of an aortic regurgitation >= 2 at discharge were associated with MV-IE. Patients with MV-IE were rarely operated on and had a poor prognosis at 2-year follow-up.